Article Text

Download PDFPDF
CASE REPORT
Clinically amyopathic dermatomyositis associated with anti-MDA5 antibody
  1. Konstantinos Parperis1,
  2. Amirali Kiyani2
  1. 1Department of Medicine, Maricopa Medical Center and University of Arizona College of Medicine, Phoenix, Arizona, USA
  2. 2Internal Medicine, Baylor College of Medicine, Houston, Texas, USA
  1. Correspondence to Dr Konstantinos Parperis, kparperi{at}email.arizona.edu

Summary

Clinically amyopathic dermatomyositis (CADM) is a rare entity that presents with cutaneous manifestations of classic dermatomyositis but without muscle weakness or abnormal muscle enzymes. It is more common in young white and Asian females. A subset of patients with CADM has a specific antibody known as anti-MDA5. These patients have a more aggressive course with distinct cutaneous features, pulmonary involvement and early death. Here, we present the case of a 64-year-old Caucasian male with no significant medical history who was admitted with marked weight loss and a painful rash for 6 months. Patient had no muscle weakness and his rash was characteristic of classic dermatomyositis. Skin biopsy was suggestive of dermatomyositis but muscle enzymes were normal. His serum was positive for anti-MDA5 antibody. Extensive workup failed to detect any malignancy but he did show non-specific interstitial pneumonia. He was treated with prednisone and mycophenolate with good clinical response.

  • connective tissue disease
  • dermatology

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors Both authors have participated in the preparation of this manuscript and contributed to the planning, conduct, reporting, conception and design, acquisition of data or analysis and interpretation of data.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.